kstew call note call focus outlook management
comfort street
releas result quarter end januari morn confer call finish littl bit ago apolog
slight delay get
share et versu market surpris reaction see earlier
note first look upsid surpris especi given somewhat cautiou commentari januari date mention
believ expect like low go quarter given manag commentari earli januari
call focus expect outlook respect manag note continu work
annual plan process earli issu guidanc may releas result said manag
comment confid abil deliv organ growth note impli guidanc
view low water mark growth improv manag also note confid abil drive
annual underli margin expans consist long rang plan note fx would headwind oper
margin also expect tax rate consist commentari earli januari manag note
continu work tax rate financi lever interest expens share repurchas point
com fortabl current street consensu ep estim ate per refinitiv
net/net noth chang view stock continu rate stock overweight given valuat manag
commentari around comfort consensu ep comfort us think market prepar back-end
load year mani pipelin mileston
raw note verbatim
question pleas feel free reach
raw note follow verbatim
report anoth quarter solid top bottom line
revenu grow th organ reflect diversifi model op profit ep constant currenc
execut top prioriti execut multipl front deliv
revenu out-performance mitg rtg driven new product launch off-set challeng cvg talk januari
emerg market grew reflect strong quarter across busi geographi
 benefit dow focu throughout organ margin improv op margin expans includ benefit
currenc
 ork convers ytd gener vs prior year
overal anoth good quarter hat excit result progress pipelin opportun
grow th time compani histori
minim invas therapi group mitg outstand quarter strong grow th surgic innov si
divis si ith strong grow th advanc energi low doubl digit advanc stapl high singl digit grow th
respiratori gi renal busi grew ith strong busi gi grew mid singl digit respiratori high singl digit
grow th renal care mid teen ith bellco renal access
restor therapi group rtg grew driven sustain momentum brain therapi high teen
neurovascular neurosurgeri neurovascular broad strength across stroke franchis ith double-digit grow th stent
retriev flow divert neuro access embol product neurosurgeri high grow th capit equip driven
stealth imag mazor midasrex launch mazor stealth edit last month receiv enthusiast feedback believ
capit equip sale lead indic spine busi spine flat quarter combin ith capit equip
use spine includ us core spine pain therapi high singl digit grow th spinal cord stimul
diabet grew quarter group face touch comp pump sale despit grew sequenti cgm grew
 ith grow th estern europ stand-alone guardian connect third consecut quarter tripl digit grow th
cardiac vascular group cvg grew hich line ith revis forecast earli januari ith mid singl digit grow th
coronari structur heart aortic peripher venou intervent divis csh strong quarter ith tavr us
ou solid momentum share gain us global market market leader mani region around orld
includ estern europ apvi grow th driven valent navion thorac stent graft system mid teen venou vein closur
inpact dcb mid singl digit grow th pacemak driven micra mid teen declin heart failur primarili driven
declin lvad result share loss heart guidelin chang af solut mid teen grow th announc epic therapeut
acquisit cvg servic solut face headw ind revenu recognit start larg order va exit
product line exclud servic solut cvg grow th ould crhf higher
emerg market perform strong grow ing repres revenu strength diversifi china south
build leadership posit med-tech invest higher grow th opportun disrupt exist market invent
new one rais amgr compani
rtg launch mazor stealth drive grow th neurosurgeri busi creat demand core spine neurovascular
limit releas react cathet continu riptid aspir cathet expect releas next gener solitair
stent ischem stent end db primari cell devic launch
cvg present tw landmark trial risk tavr studi result rap-it trial ith tyrx envelop launch
next gener tavr valv evolut low er profil improv predict placement reveal linq launch
 ell next convent crt-d base polari high pow ere platform new dcb av fistula market
around year end fda approv micra av pacemak enabl access pacemak market today
mitg expand diseas specialti area tristapl capnographi launch launch next gener sonosciss
platform robot launch sever meet ith regulatori bodi around orld includ fda surgeon
use platform believ platform combin ith instrument surgeon train center around orld ill expand market
diabet continu introduct new geographi around orld expect launch advanc hybrid
close loop system ith bluetooth minim gener algorithm improv time rang ill reduc
burden carb count expect submit non-adjunct test guardian sensor next month
expect next five quarter excit bring innov product market
equal excit longer term cvg sever product creat larg market includ intrepid simplic system
disrupt market ith program af extravascular new multi billion grow th opportun rtg interstim micro sacral
nerv stimul bladder control ith mri compat db develop close loop system also plan introduc cranial
expect launch product mitg next five year diabet fda grant breakthrough design
person close loop system time person algorithm autom insulin deliveri person basi predict
diagnost uniqu individu also advanc cgm pipelin reduc need calibr make sensor smaller
longer last pipelin deeper highlight mention today
takeaw ay execut ell pipelin
revenu organ neg fx impact ep
adjust margin increas quarter ytd includ tailw ind currenc
drive underli margin improv execut enterpris excel program
sg quarter improv
adjust tax rate better expect due increas benefit ith final tax ow ed return expect
includ non recur tax benefit exclud tax rate ould ith chang ith tax reform
still expect
quarter improv cash flow prioriti
remain commit disciplin capit deploy minimum back sharehold ytd return includ net
share repurchas result pay-out adjust net incom
also remain focu increas return invest capit strong execut disciplin invest process ith
tuck-in acquisit focu ith strong grow ing dividend creat valu sharehold
organ revenu grow th expect hich top half prior rang reflect
continu strength mitg rtg off-set headw ind cvg difficult comp diabet expect rtg sale grow th
expect mitg grow th /- /- continu expect cvg sale grow th
expect diabet grow th low mid teen
expect mitg rtf cvg look like diabet roughli flat year expect grow th diabet
bit anomali given prior year comparison hen could clear backlog sensor order year stack basi
grow th look normal
move next year believ grow th repres like bottom expect grow th improv diabet compani
margin continu expect underli expans deliv absorb headw ind product mix china
earn given perform three quarter increas ep guidanc
recent exchang rate hold full year fx despit headw ind top line given hedg benefit fx expect
modest posit oper margin earn cash flow
heel strong perform month increas rang billion billion
expect addit progress convert non-gaap earn continu drive increas focu throughout
question outlook
organ revenu growth rate hen look full year forecast impli /- that hat
 refer low point
organ compani come strong guidanc close talk pipelin look
first half mayb low end back half high end think that right ay think pipelin back
end load quarter progress youll see benefit grow th rate product introduct start point
carri ill get approv countri product introduct gradual increas back end load
er first half higher second half mention grow th rate low point
guidanc impli organ said expect bottom would drive improv
diabet comp comp back half difficult chang expect cvg improv bring new
product ill anniversari revenu recognit chang cvg
margin outlook next year confid long rang plan continu next year abl deliv
underli margin expans
margin constant currenc fx fx oper margin line see headw ind expect littl
headw ind oper margin line least right
put take continu ork annual plan earli issu outlook hat see today
confid abil deliv plu organ revenu grow th despit pipelin eight back end year line ith
long rang plan also confid abil continu drive annual underli margin expans also consist
 ith long rang plan continu model tax rate next year betw een ere continu ork tax rate
 ell financi lever point comfort ith current street consensu fx basi headw ind
expect continu next year ould expect fx sever hundr million dollar top line
headw ind modest impact bottom line
chang tax rate growth commun januari growth outlook long rang plan hold
next year oper perform basi line addit financi lever includ tax rate
 hat ork look interest expens line item also share repurchas
comfort consensu estim one think compound-annual-growth-rate big headw ind tax
rate fx headw ind mention comfort ith current street consensu think strength pipelin
think back half year carri
question cardiac vascular group perform outlook
term upcom meet set expect come meet tyrx studi
posit frame market opportun tw late break low risk tavr tyrx accept ill
simultan public high risk devic implant use tyrx product right case use tyrx
upcom trial think term basi death stroke superior need chang
paradigm low risk tavr probabl surgeri probabl come tabl seen patient highli
enthusiast less invas approach get experienc see durabl data ill see signific patient pull
expand market
dcb perform ere pleas ith outcom especi given hat seen commun januari ith
account press paus button sinc commun come sinc
manufactur data come market get comfort ith product signific efficaci benefit
regular balloon av fistula indic continu ork btk
lvad perform tw issu mention approv heartmat chang guidelin us market think dow
basic patient ith lvad put bottom list ith transplant think ill headw ind next sever
intrepid move transept continu enrol apollo studi drop enrol rate ake coapt
continu ork pipelin transfemor make strateg decis small make make transfemor
right transept design decis engin smaller solut go ith larger version still ip
simplic trial might see data enrol med trial hich ill basi pma approv data avail earli
question diabet
think diabet go forward probabl talk comp see deceler grow th
say come difficult comp back half last year increas cgm capac anniversari
anima that longer benefit also one last big payor approv reimburs last quarter
diabet revenu quarter higher quarter ago grow th rate tough comp
 ill carri grow th rate stand point expect low point expect comp normal return grow th
full year comp ill normal confid diabet ill grow corpor averag
diabet believ person close loop go ay believ close loop achiev today algorithm
across patient tomorrow ill person person diagnost think ill transform system
thrill breakthrough design fda ada think ill outlin detail around person close
question robot program
updat surgic robot program surgeon use robot system opportun see
procedur realli impress experi track launch procedur begun collect clinic
data ill arrang opportun see product live
make sens increas spend pipelin fund spend money fund pipelin alw ay look
product share betw een differ group transfer technolog miniatur batteri technolog good
exampl move across differ group
irr track versu expect focus improv compani pipelin part also look
acquisit make sure strong
expens growth sg look better product go market initi opportun reduc number
manufactur site effort factori improv effici line enterpris excel program reduc overal
emerg market feel good think opportun improv penetr exist product
question pleas feel free reach ith question
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
